Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

From biosensor chips to wastewater epidemiology, the COVID-19 pandemic is accelerating the development of next-generation disease diagnostics.

Why it matters: If we're going to stop a disease, we first have to know who has it and where. New technologies promise to provide doctors with more reliable intelligence about who in a community has a disease — and who is likely to get seriously ill.

What's new: In response to COVID-19, a number of researchers and startups are pushing new diagnostic technologies that take advantage of cheaper and quicker genetic sequencing to provide far more accurate and rapid intelligence on just where COVID-19 is, and where it might be going.

  • "With the coronavirus, we are being catapulted into a new era," says Milan Patel, the CEO of the DNA-based diagnostic company PathogenDx.

Some of the most promising new technologies involve what are called molecular electronics biosensor chips.

  • While the RT-PCR tests used for diagnosing active infections repeatedly copy specific viral sequences in a sample before they reach detectable levels, biosensors can detect the presence of viral genes in a sample as it is, producing results much more rapidly.
  • As it becomes cheaper, such technology holds the promise of being able to test an entire population for specific viruses, or even scan the physical environment for signs of viral contamination.
  • "Imagine an active surveillance system that pings offices, shops, airplanes, train stations to see if you have hot spots for a given pathogen or infectious disease," says Barry Merriman, the co-founder of Roswell Biotechnologies, a startup leading the way on developing commercial biosensors for disease surveillance.

A cruder form of environmental surveillance is already under way — underground. Researchers in several cities have begun testing city sewage for the presence of SARS-CoV-2 viral RNA.

  • Sewage is unique as a diagnostic source in that it represents a near-universal sample of what is in — or coming out of — the community. As Mariana Matus, co-founder of the startup Biobot Analytics, told NPR: "Every person that is using the toilet has a voice."

What to watch: Next-generation diagnostics can go beyond simply determining who is and isn't infected. A number of researchers are working on tests that can identify biomarkers that might predict just how sick a COVID-19 patient will become.

  • Scientists at the New York University College of Dentistry have developed a mobile app that takes four biomarkers found in blood tests that were significantly elevated in COVID-19 patients — along with known risk factors like age and sex — and uses a machine-learning algorithm to produce a predicted severity score that runs from 0 to 100.
  • Quanterix has developed a highly sensitive antibody test capable of indicating early in a COVID-19 infection whether a patient is likely to develop an immune overreaction — called a cytokine storm — that can lead to a more severe case. "That allows for an entirely different insight on disease severity and treatment options," says Kevin Hrusovsky, Quanterix's CEO.

The catch: "Testing is a conservative field," notes PathogenDx's Patel. There's good reason for that — we've already witnessed the damage that inaccurate tests can do — but it does mean that new technologies may be rolled out too slowly to make a major difference for the first wave of the pandemic.

The bottom line: COVID-19 struck us in a surprise attack, but better diagnostics could help ensure that we aren't caught off guard again.

Go deeper: Coronavirus diagnostic test pricing is relatively tame

Go deeper

Sep 13, 2020 - Health

Pfizer preparing to distribute COVID vaccine by year-end, CEO says

Pfizer CEO Albert Bourla told CBS News' "Face the Nation" Sunday that his company will know whether its coronavirus vaccine is effective by the end of October and that it has already manufactured hundreds of thousands of doses in anticipation that the vaccine will receive FDA approval.

Why it matters: There has been a major push by the Trump administration to get a coronavirus vaccine to the public this fall, though it may only be available for certain high-risk groups. The Centers for Disease Control and Prevention has already urged governors to have vaccine distribution centers ready by November.

Sep 13, 2020 - Politics & Policy

Infectious-disease expert: "Telling the truth never causes panic"

Michael Osterholm, a renowned infectious-disease expert and the director of the Center for Infectious Disease Research and Policy at the University of Minnesota, said on NBC's "Meet the Press" Sunday that leaders must tell the truth when it comes to public health and that "telling the truth never causes panic."

Why it matters: Host Chuck Todd asked Osterholm if President Trump had made a mistake by not being upfront with the American people about the dangers of COVID-19 and the threat of a pandemic. In an interview for Bob Woodward's new book "Rage," Trump said that he was purposefully "playing it down" so as not to create a "panic."

Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: U.S. to buy 500 million more Pfizer doses to share with the world — Fauci: Vaccine could be available for children 5–11 in "weeks" — Biden to get booster shot on camera.
  2. Health: Care for kidney disease plummeted in the pandemic — Manufacturers warn rapid test shortages are coming — Study: Pandemic cut U.S. life expectancy by more than 9 million years.
  3. Politics: Brazil's health minister tests positive during UN summit in N.Y. — Massachusetts State Police union sues over governor's vaccine mandate — Biden to push vaccine-sharing at UN, but boosters at home.
  4. Education: Education Department investigating Texas mask mandate ban — D.C. schools to require teachers, staff to receive vaccine without testing option — More schools using "test-to-stay" strategy to minimize quarantines.
  5. Variant tracker: Where different strains are spreading.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!